Cargando…
Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study
OBJECTIVES: To describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months. DESIGN: Prospective, multinational, and obs...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioScientifica
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232638/ https://www.ncbi.nlm.nih.gov/pubmed/22048967 http://dx.doi.org/10.1530/EJE-11-0740 |
_version_ | 1782218387531759616 |
---|---|
author | Jakob, F Oertel, H Langdahl, B Ljunggren, O Barrett, A Karras, D Walsh, J B Fahrleitner-Pammer, A Rajzbaum, G Barker, C Lems, W F Marin, F |
author_facet | Jakob, F Oertel, H Langdahl, B Ljunggren, O Barrett, A Karras, D Walsh, J B Fahrleitner-Pammer, A Rajzbaum, G Barker, C Lems, W F Marin, F |
author_sort | Jakob, F |
collection | PubMed |
description | OBJECTIVES: To describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months. DESIGN: Prospective, multinational, and observational study. METHODS: Data on prior bisphosphonate use, clinical fractures, back pain visual analog scale (VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed using a repeated measures model. RESULTS: Of the 1581 enrolled patients with follow-up data, 1161 (73.4%) had a history of prior bisphosphonate use (median duration: 36 months). Of them, 169 (14.6%) sustained ≥1 fracture during 36-month follow-up. Adjusted odds of fracture were significantly decreased at each 6-month interval compared with the first 6 months of teriparatide treatment: 37% decrease in the 12 to <18 months period during teriparatide treatment (P=0.03) and a 76% decrease in the 12- to 18-month period after teriparatide was discontinued (P<0.001). Significant reductions in back pain and improvement in HRQoL were observed. CONCLUSIONS: Postmenopausal women with severe osteoporosis previously treated with bisphosphonates had a significant reduction in the incidence of fractures compared with the first 6 months of therapy, a reduction in back pain and an improvement in HRQoL during up to 18 months of teriparatide treatment. These outcomes were still evident for at least 18 months after teriparatide was discontinued. The results should be interpreted in the context of an uncontrolled, observational study in a routine clinical setting. |
format | Online Article Text |
id | pubmed-3232638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioScientifica |
record_format | MEDLINE/PubMed |
spelling | pubmed-32326382012-01-01 Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study Jakob, F Oertel, H Langdahl, B Ljunggren, O Barrett, A Karras, D Walsh, J B Fahrleitner-Pammer, A Rajzbaum, G Barker, C Lems, W F Marin, F Eur J Endocrinol Clinical Study OBJECTIVES: To describe fracture rates, back pain, and health-related quality of life (HRQoL) in postmenopausal women with osteoporosis and prior bisphosphonate therapy, treated with teriparatide for up to 18 months and followed up for a further 18 months. DESIGN: Prospective, multinational, and observational study. METHODS: Data on prior bisphosphonate use, clinical fractures, back pain visual analog scale (VAS), and HRQoL (EQ-5D) were collected over 36 months. Fracture data were summarized in 6-month intervals and analyzed using logistic regression with repeated measures. Changes from baseline in back pain VAS and EQ-VAS were analyzed using a repeated measures model. RESULTS: Of the 1581 enrolled patients with follow-up data, 1161 (73.4%) had a history of prior bisphosphonate use (median duration: 36 months). Of them, 169 (14.6%) sustained ≥1 fracture during 36-month follow-up. Adjusted odds of fracture were significantly decreased at each 6-month interval compared with the first 6 months of teriparatide treatment: 37% decrease in the 12 to <18 months period during teriparatide treatment (P=0.03) and a 76% decrease in the 12- to 18-month period after teriparatide was discontinued (P<0.001). Significant reductions in back pain and improvement in HRQoL were observed. CONCLUSIONS: Postmenopausal women with severe osteoporosis previously treated with bisphosphonates had a significant reduction in the incidence of fractures compared with the first 6 months of therapy, a reduction in back pain and an improvement in HRQoL during up to 18 months of teriparatide treatment. These outcomes were still evident for at least 18 months after teriparatide was discontinued. The results should be interpreted in the context of an uncontrolled, observational study in a routine clinical setting. BioScientifica 2012-01 /pmc/articles/PMC3232638/ /pubmed/22048967 http://dx.doi.org/10.1530/EJE-11-0740 Text en © 2012 European Society of Endocrinology http://www.bioscientifica.com/journals/reuselicenceeje/ This is an Open Access article distributed under the terms of the European Journal of Endocrinology's Re-use Licence (http://www.bioscientifica.com/journals/reuselicenceeje/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Clinical Study Jakob, F Oertel, H Langdahl, B Ljunggren, O Barrett, A Karras, D Walsh, J B Fahrleitner-Pammer, A Rajzbaum, G Barker, C Lems, W F Marin, F Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study |
title | Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study |
title_full | Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study |
title_fullStr | Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study |
title_full_unstemmed | Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study |
title_short | Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study |
title_sort | effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the european forsteo observational study |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3232638/ https://www.ncbi.nlm.nih.gov/pubmed/22048967 http://dx.doi.org/10.1530/EJE-11-0740 |
work_keys_str_mv | AT jakobf effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT oertelh effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT langdahlb effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT ljunggreno effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT barretta effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT karrasd effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT walshjb effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT fahrleitnerpammera effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT rajzbaumg effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT barkerc effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT lemswf effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy AT marinf effectsofteriparatideinpostmenopausalwomenwithosteoporosispretreatedwithbisphosphonates36monthresultsfromtheeuropeanforsteoobservationalstudy |